Why Is Approximately 55% of Patients Remaining Recurrence-Free Still Not Enough to Change the Assessment?

  • In the latest adjuvant pancreatic ductal adenocarcinoma (PDAC) data, 11 of 20 evaluable patients remained recurrence-free, or approximately 55%, with median follow-up of approximately 17 months. JPMorgan’s focus is how much efficacy this result adds compared with mFOLFIRINOX chemotherapy alone.
  • The bank also compared the phase-one iNeST study, which used a regimen combining atezo and mFOLFIRINOX. Its overall data were likewise difficult to distinguish from mFOLFIRINOX alone. Although the data for patients who mounted an immune response in iNeST merit attention, the bank remains cautious in its assessment of overall efficacy.

What Did the Safety Data Show?

  • The report lists the incidence of intismeran-related grade 3 or higher treatment-emergent adverse events at 5%, or 1 of 20 patients. This describes the burden of drug-related serious adverse events in the group; assessing efficacy requires a comparison of recurrence-free outcomes with the chemotherapy benchmark.
  • The two types of evidence correspond to different thresholds: safety concerns how well the treatment is tolerated, while the difference in efficacy concerns how much clinical value adding intismeran can provide. JPMorgan’s cautious assessment this time rests primarily on the latter question.

What Evidence Needs to Catch Up with an 80 billion Dollar Market Capitalization?

  • JPMorgan believes Moderna’s approximately 80 billion dollar market capitalization already reflects expectations of broad efficacy for intismeran. However, the product’s economic rights must be shared, so only part of the value it creates belongs to Moderna; to explain the current valuation, the bank would need to adopt substantially more optimistic assumptions about both intismeran and the broader platform.
  • Positive new data in indications beyond melanoma are therefore particularly important to supporting this valuation rationale. The report maintains an “Underweight” rating on Moderna and is watching the intismeran adjuvant melanoma presentation scheduled for 24 October 2026; this near-term event and the accumulation of evidence in other indications relate respectively to the performance of an individual program and the platform’s range of applicability.